FindTrial
Sign In

Quantitative analysis of BPH and Prostate Cancer by using T2 and R2 star mapping

Precision prediction of time to development of CRPC and clinical utility based on mpMRI imaging

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043016
Enrollment
Unknown
Registered
2021-02-04
Start date
2021-02-10
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:prostate biopsy
Index test:T2* value

Sponsors

the First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) MRI conducted <14 days before prostate biopsy; (2) the prostate MRI included T2-weighted imaging, DWI and T2 star mapping; (3) avoid inflammation, bleeding, cystic change and other areas that affect the measurement

Exclusion criteria

Exclusion criteria: (1) prior PCa treatment, including focal therapy, surgery, hormones, or radiation therapy; (2) T2* and conventional T2W imaging artifacts that made the examination non-diagnostic.

Design outcomes

Primary

MeasureTime frame
T2* value;R2* value;—

Countries

China

Contacts

Public ContactHuang Yuhua

the First Affiliated Hospital of Soochow University

hyhjxnc@163.com+86 18913752992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026